Short Interest in CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) Decreases By 49.6%

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) saw a significant drop in short interest during the month of May. As of May 29th, there was short interest totaling 42,484 shares, a drop of 49.6% from the May 14th total of 84,316 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average trading volume of 38,729 shares, the days-to-cover ratio is presently 1.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised CollPlant Biotechnologies from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, CollPlant Biotechnologies currently has a consensus rating of “Hold” and a consensus target price of $11.50.

CollPlant Biotechnologies Trading Up 1.5%

Shares of NASDAQ CLGN opened at $0.34 on Friday. CollPlant Biotechnologies has a twelve month low of $0.27 and a twelve month high of $3.23. The stock has a fifty day simple moving average of $0.39 and a 200-day simple moving average of $0.95. The stock has a market capitalization of $4.89 million, a PE ratio of -0.23 and a beta of 1.57.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Friday, May 29th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. CollPlant Biotechnologies had a negative return on equity of 218.81% and a negative net margin of 683.68%.The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.46 million.

Institutional Investors Weigh In On CollPlant Biotechnologies

A hedge fund recently raised its stake in CollPlant Biotechnologies stock. Pinnacle Associates Ltd. grew its position in CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 9.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 557,193 shares of the company’s stock after buying an additional 50,000 shares during the quarter. Pinnacle Associates Ltd. owned 4.36% of CollPlant Biotechnologies worth $780,000 as of its most recent filing with the Securities and Exchange Commission. 21.69% of the stock is currently owned by institutional investors.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.